Stimulating Interactions


Fay Christodoulou, CSO, Miroculus

The notion of small molecules that detect dozens of cancers may sound like something out of a science-fiction novel. But for Christodoulou and her peers at Miroculus, it’s more akin to a modern-day reality. The company has trained its sights on microRNA, which Christodoulou describes as small molecules that reflect a person’s health state and which might be used as […]

Read more

David Whitlock of AOBiome | Q&A

Chemical engineer David Whitlock has made a splash in the media as of late, due to his lack of “splash”—as in the man hasn’t bathed in 12 years. The reason behind such a choice? David is working to defend the bacteria that live on his skin—as it does on ours—but Whitlock also believes it’s in our best interest to keep […]

Read more

How Bell Biosystems is using naturally magnetic bacteria to track cell therapies

With FDA calling for non-invasive new tracking systems to accompany cell therapies, Bell Biosystems Inc. wants its Magnelle trackers to become the technology of choice. While the magnetic organelles’ longevity and strong signals lend the agents advantages for large animal and human studies, the company is hoping to make its mark in the preclinical space before tackling what will likely […]

Read more

Amarantus Announces Issuance of Australian Patent

Amarantus Announces Issuance of Australian Patent Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, today announced the issuance of Australian patent no. 61/057,713 covering the use of Eltoprazine for the treatment of various neurological and mental disorders, including Parkinson’s disease, […]

Read more

Blueprint Genetics Plans to Boost Inherited Disease Panel Portfolio Next Year

Finnish hereditary disease diagnostics firm Blueprint Genetics plans to significantly expand its portfolio of clinical gene panel tests next year, and in the meantime has been pushing into new territories, including the US. The Helsinki-based firm started offering diagnostic gene panels for inherited cardiovascular disorders two years ago, using a targeted sequencing technology called OS-Seq that one of its co-founders […]

Read more

Symic Biomedical Selects Osteoarthritis Clinical Candidate

Symic Biomedical, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the selection of SB-061 as the company’s first osteoarthritis clinical candidate. In preclinical studies, SB-061 was shown to reduce pain and cartilage degradation in models of osteoarthritis. SB-061, which will be administered as an intra-articular injection, is designed to prevent the […]

Read more

A guy who hasn’t showered in 12 years just helped launch a skin care company

Forgoing a shower, even for a day, makes some people want to hide from society and double up on the deodorant. For Dave Whitlock, this is simply life as usual. The chemical engineer and MIT grad decided back in 2003 to stop showering after discovering that animals harness bacteria in mud to stay odor-free. Called Nitrosomonas, these bacteria break down […]

Read more

A new dawn for cataracts

On Thursday, November 6, scientists from ViewPoint Therapeutics published an article titled “Pharmacological chaperone for α-crystallin partially restores transparency in cataract models” in Science Magazine. The lead author: ViewPoint’s founder and CSO, Leah Makley. The summary below is from the linked perspective in the same issue. Cataract, a clouding of the eye lens, is the major cause of blindness in […]

Read more

Symic Biomedical Advances First Product Candidate, SB-030, Into Clinical Development

Symic Biomedical, a clinical-stage biotherapeutics platform company developing compounds that target the extracellular matrix (ECM), today announced the treatment of the first patient in its Phase 1/2 clinical Study in Humans to Investigate the Efficacy and Safety of Luminal SB-030 Delivery in Peripheral Artery Disease (SHIELD Trial). The study will evaluate the safety and efficacy of SB-030 (previously SBCV-030), a […]

Read more

Amarantus seeks US FDA orphan drug status for eltoprazine

Amarantus Bioscience Holdings, Inc., a biotechnology company, has submitted a request to the US FDA for orphan drug designation (ODD) for eltoprazine in the treatment of levodopa-induced dyskinesia (PD-LID). “A successful application to the US FDA for ODD for eltoprazine in PD LID would complete the transition of our therapeutics portfolio into the orphan drug arena, thereby squarely positioning Amarantus […]

Read more
Page 4 of 7« First...23456...Last »


953 Indiana St.
San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter